We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comment on 'Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab'.
- Authors
Shimokawa, H; Uramoto, H; Tanaka, F
- Abstract
A response by H. Shimokawa, H. Uramoto, and F. Tanaka to a letter to the editor on their article "Pre-treatment levels of circulating free IGF-I identify NSCLC patients who derive clinical benefit from figitumumab," in the 2011 issue is presented.
- Subjects
LETTERS to the editor; SMALL cell lung cancer; SOMATOMEDIN
- Publication
British Journal of Cancer, 2011, Vol 105, Issue 9, p1465
- ISSN
0007-0920
- Publication type
letter
- DOI
10.1038/bjc.2011.412